<DOC>
	<DOCNO>NCT02468323</DOCNO>
	<brief_summary>This study aim compare quality perioperative antiemesis palonosetron ondansetron patient undergoing cesarean section</brief_summary>
	<brief_title>Prophylactic Antiemetic Efficacy Palonosetron Versus Ondansetron Cesarean Sections Under Regional Anesthesia</brief_title>
	<detailed_description>Perioperative nausea vomiting ( PONV ) relate spinal block anesthesia common event unpleasant pregnant woman . Its incidence reach 80 % high-risk patient , remain high despite emergence new antiemetic drug . Episodes untreated result prolong stay post-anesthetic care unit ( PACU ) rehospitalization result significant increase overall cost health care . The purpose prophylaxis PONV therefore decrease incidence , stress patient , improve quality safety surgical procedure reduce hospital cost . Antagonists 5-hydroxytryptamine 3 subtype receptor widely use effective PONV due efficacy favorable side-effect profile . Palonosetron new potent drug generation5 second-HT antagonist improve profile act longer . Recent study compare ondansetron palonosetron high-risk patient head neck surgery laparoscopic surgery disclose palonosetron far superior ondansetron especially 2-24 hour surgery . But study caesarean compare two drug . This prospective , randomize , double-blind , placebo control , design evaluate efficacy palonosetron compare ondansetron placebo prevention nausea vomit patient undergo cesarean delivery spinal anesthesia .</detailed_description>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Antiemetics</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>American Society Anesthesiologists class I II Scheduled cesarean section Maternal Child Hospital Brasilia , Federal District , Brazil patient receive antiemetic , diabetic , allergic study drug , corticosteroid use , psychoactive drug , patient vomit course gastrointestinal disease , eclampsia , heart disease , smoker , evidence fetal distress , psychiatric disease refuse participate .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PONV</keyword>
	<keyword>Palonosetron</keyword>
	<keyword>Ondansetron</keyword>
	<keyword>Cesarean section</keyword>
</DOC>